The road to
Health Economic Software

We recognize that the clinical value of new innovations in biotech, pharma, and medtech is not fixed. Instead, it depends on the specific settings in which they are used. Traditional evaluations of these innovations often provide a limited view, focusing on cost-effectiveness and health outcomes in a single setting. These evaluations yield conclusions that, while useful, do not capture the full potential of the innovations.

From our experience in academia, we observed that this limited approach often overlooks significant potential and fails to fully exploit the clinical value of new products. Companies miss opportunities to demonstrate the broader benefits of their innovations, which can lead to underutilization and undervaluation in the market.

We believe in shifting from static evaluations to dynamic assessments of value. By evaluating cost-effectiveness, cost-utility, and cost-benefit across various settings, we can unlock more value from these technologies. Our software enables comprehensive evaluations, showing variations in value across different contexts. This dynamic approach empowers stakeholders—doctors, hospitals, and others—to see the added value of innovations in their specific settings, rather than relying on generic evaluations.

We call this 'Health Economic Software’. Health Economic Software helps companies maximize the clinical value of their innovations, ensuring they reach their full potential and improve healthcare outcomes.